Group 1B phospholipase A2 inactivation suppresses atherosclerosis and metabolic diseases in LDL receptor-deficient mice

Atherosclerosis

Volumn 234, Issue 2, 2014, Pages 377-380

  Hollie, Norris I ^a   Konaniah, Eddy S ^a   Goodin, Colleen ^a   Hui, David Y ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Glucose tolerance; Lipid and lipoprotein metabolism; Phospholipase

Indexed keywords

CHOLESTEROL; FAT; GLUCOSE; INSULIN; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PHOSPHOLIPASE A2 GROUP IB; SUCROSE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; BIOLOGICAL MARKER; FAT INTAKE; GLUCOSE BLOOD LEVEL; PLA2G1B PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ROOT; ARTICLE; ATHEROSCLEROSIS; DIET; DIET RESTRICTION; ENZYME INACTIVATION; FAST PROTEIN LIQUID CHROMATOGRAPHY; GENE INACTIVATION; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MALE; METABOLIC DISORDER; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; ANIMAL; BLOOD; C57BL MOUSE; CALORIC INTAKE; DEFICIENCY; DISEASE MODEL; ENZYMOLOGY; FAT INTAKE; GENETICS; GLUCOSE BLOOD LEVEL; HYPERINSULINISM; HYPERLIPIDEMIAS; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIETARY FATS; DISEASE MODELS, ANIMAL; ENERGY INTAKE; GROUP IB PHOSPHOLIPASES A2; HYPERGLYCEMIA; HYPERINSULINISM; HYPERLIPIDEMIAS; INSULIN; LIPIDS; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, LDL; WEIGHT GAIN;

EID: 84900872163     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.03.027     Document Type: Article

References (19)

1. Agouridis A.P., Filippatos T.D., Tsimihodimos V., Elisaf M.S. Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism. Expert Rev Cardiovasc Ther 2011, 9:355-366.
2. Nelson R.H., Miles J.M. The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes. Expert Opin Pharmacother 2005, 6:2483-2491.
3. Altmann S.W., Davis H.R., Zhu L.-J., Yao X., Hoos L.M., Tetzloff G., et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 2004, 303:1201-1204.
4. Wilson S.G., Adam G., Langdown M., Reneland R., Braun A., Andrew T., et al. Linkage and potential association of obesity-related phenotypes with two genes on chromosome 12q24 in a female dizygous twin cohort. Eur J Hum Genet 2006, 14:340-348.
5. Richmond B.L., Hui D.Y. Molecular structure and tissue-specific expression of the mouse pancreatic phospholipase A2 gene. Gene 2000, 244:65-72.
6. Nevalainen T.J., Gronroos J.M., Kortesuo P.T. Pancreatic and synovial type phospholipases A2 in serum samples from patients with severe acute pancreatitis. Gut 1993, 34:1133-1136.
7. Aufenanger J., Samman M., Qunitel M., Fassbender K., Zimmer W., Bertsch T. Pancreatic phospholipase A2 activity in acute pancreatitis: a prognostic marker for early identification of patients at risk. Clin Chem Lab Med 2002, 40:293-297.
8. Richmond B.L., Boileau A.C., Zheng S., Huggins K.W., Granholm N.A., Tso P., et al. Compensatory phospholipid digestion is required for cholesterol absorption in pancreatic phospholipase A(2) deficient mice. Gastroenterology 2001, 120:1193-1202.
9. 2-deficient mice. Am J Physiol 2002, 283:E994-E1001.
10. 2 and diet-induced obesity. FASEB J 2010, 24:2516-2524.
11. Labonte E.D., Kirby R.J., Schildmeyer N.M., Cannon A.M., Huggins K.W., Hui D.Y. Group 1B phospholipase A2-mediated lysophospholipid absorption directly contributes to postprandial hyperglycemia. Diabetes 2006, 55:935-941.
12. 2 exacerbates diet-induced obesity and insulin resistance in mice. Int J Obes 2011, 35:877-881.
13. 2 deficiency protects against diet-induced hyperlipidemia in mice. JLipid Res 2011, 52:2005-2011.
14. Lingrel J.B., Pilcher-Roberts R., Basford J.E., Manoharan P., Neumann J., Konaniah E.S., et al. Myeloid-specific Kruppel-like factor 2 inactivation increases macrophage and neutrophil adhesion and promotes atherosclerosis. Circ Res 2012, 110:1294-1302.
15. 2 inhibitor methyl indoxam suppresses diet-induced obesity and glucose intolerance in mice. Br J Pharmacol 2009, 157:1263-1269.
16. Hollie N.I., Cash J.G., Matlib M.A., Wortman M., Basford J.E., Abplanalp W., et al. Micromolar changes in lysophosphatidylcholine concentration cause minor effects on mitochondrial permeability but major alterationsin function. Biochim Biophys Acta 2013, 1841:888-895.
17. Nordestgaard B.G., Chapman M.J., Humphries Steve E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur Heart J 2013, 34:3478-3490.
18. Ahmed M.H., Byrne C.D. Potential therapeutic uses for ezetimibe beyond lowering LDL-c to decrease cardiovascular events. Diabetes Obes Metab 2010, 12:958-966.
19. Chambot D. Non-systemic drugs: a critical review. Curr Pharm Des 2012, 18:1434-1445.